Abstract | BACKGROUND: METHODS: In the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial, 2569 ambulatory chronic HF patients with left ventricular ejection fraction ≤ 35% and serum creatinine level ≤ 2.5mg/dl were randomized to receive either placebo (n=1284) or enalapril (n=1285). Of the 2502 patients with baseline serum creatinine data, 1036 had CKD (estimated glomerular filtration rate <60 ml/min/1.73 m(2)). RESULTS: Overall, during 35 months of median follow-up, all-cause mortality occurred in 40% (502/1252) and 35% (440/1250) of placebo and enalapril patients, respectively (hazard ratio {HR}, 0.84; 95% confidence interval {CI}, 0.74-0.95; p=0.007). All-cause mortality occurred in 45% and 42% of patients with CKD (HR, 0.88; 95% CI, 0.73-1.06; p=0.164), and 36% and 31% of non-CKD patients (HR, 0.82; 95% CI, 0.69-0.98; p=0.028) in the placebo and enalapril groups, respectively (p for interaction=0.615). Enalapril reduced cardiovascular hospitalization in those with CKD (HR, 0.77; 95% CI, 0.66-0.90; p<0.001) and without CKD (HR, 0.80; 95% CI, 0.70-0.91; p<0.001). Among patients in the enalapril group, serum creatinine elevation was significantly higher in those without CKD (0.09 versus 0.04 mg/dl in CKD; p=0.003) during first year of follow-up, but there was no differences in changes in systolic blood pressure (mean drop, 7 mm Hg, both) and serum potassium (mean increase, 0. /L, both). CONCLUSIONS:
Enalapril reduces mortality and hospitalization in SHF patients without significant heterogeneity between those with and without CKD.
|
Authors | C Barrett Bowling, Paul W Sanders, Richard M Allman, William J Rogers, Kanan Patel, Inmaculada B Aban, Michael W Rich, Bertram Pitt, Michel White, George C Bakris, Gregg C Fonarow, Ali Ahmed |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 167
Issue 1
Pg. 151-6
(Jul 15 2013)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 22257685
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Elsevier Ireland Ltd. |
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Enalapril
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Double-Blind Method
- Enalapril
(therapeutic use)
- Female
- Follow-Up Studies
- Heart Failure, Systolic
(drug therapy, mortality)
- Hospitalization
(trends)
- Humans
- Male
- Middle Aged
- Renal Insufficiency, Chronic
(drug therapy, mortality)
- Treatment Outcome
|